An interventional study of Media Intervention and Quality-of-Life Assessment in Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma and Cervical Squamous Cell Carcinoma, Not Otherwise Specified, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Carcinoma, Adenosquamous with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Adenosquamous · United States.
Among the 23 studies in Carcinoma, Adenosquamous with a site in United States, this one is the 11th largest by enrollment, is one of 2 that started in 2020, is the only one with no phase, and was the 18th registered.
33 studies on the registry are indexed under Carcinoma, Adenosquamous; 7 are open to participants now.
Browse Carcinoma, Adenosquamous studies →4 of the 23 studies in Carcinoma, Adenosquamous with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+ · Women only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Israel, Puerto Rico
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–72
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Carcinoma, Adenosquamous studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4
First in 2000; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 42 across 32 interventional studies indexed under Carcinoma, Adenosquamous.
Median enrollment 37 across the 23 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 2 studies filed under Carcinoma, Adenosquamous — fewer than ten, so there is no comparison to draw.
3 of the studies in Carcinoma, Adenosquamous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04622670M.D. Anderson Cancer CenterYoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer | 2027-01-31 |
| NCT02133196National Cancer Institute (NCI)T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | 2027-10-23 |
| NCT04858334National Cancer Institute (NCI)APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Carcinoma, Adenosquamous with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial studies how well yoga therapy works during chemotherapy and radiation treatment in improving physical and emotional well-being in patients with stage IB2-IIIB cervical cancer. Yoga therapy may help to balance the mind and body through exercise, meditation (focusing thoughts), and control of breathing and emotions.
PRIMARY OBJECTIVE:
I. Establish feasibility of delivering a yoga therapy program during chemotherapy and radiation therapy (CRT) for loco-regionally advanced cervical cancer undergoing chemo-radiotherapy.
SECONDARY OBJECTIVES:
I. Measure the effects and variance of yoga on fatigue, depression, anxiety, pelvic pain and over-all quality of life (QOL) in cervical cancer (CxCa) patients undergoing primary treatment with CRT.
II. Examine changes in other psychosocial outcomes including ability to find meaning in the illness, spirituality and sexuality.
EXPLORATORY OBJECTIVE:
I. Evaluate whether markers of stress response (plasma levels of other pro-inflammatory cytokines, including interleukin-6 [IL-6], and IL-8, IL-10, VEGF, and CRP) change in response to yoga therapy and their association with fatigue, depression, anxiety, pelvic pain, meaning in the illness, experience, spirituality, and QOL in CxCa patients undergoing primary CRT.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (YOGA GROUP): Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment and receive a yoga manual and DVD during and after CRT.
GROUP II (WAIT LIST CONTROL): Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who are pregnant
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over and receive a yoga manual and DVD during and after CRT.
Other: Media Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Survey Administration · Procedure: Yoga
Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
Other: Media Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Survey Administration
Receive DVD
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
Ancillary studies
Attend yoga class
Also known as: Yoga Therapy
Enrollment to the yoga therapy protocol
90 patients will be screen to obtain at least 40 who are eligible and consent
Time frame: Baseline up to 3 months post CRT
Adherence to the yoga therapy protocol
At least 10 patients in the YG group must complete at least 50% of the required yoga sessions
Time frame: Baseline up to 3 months post CRT
Completion in the yoga therapy protocol
At least 25 of the 40 patients must complete any of the follow up measure between T3 and T5 in order to declare this study feasible
Time frame: Baseline up to 3 months post CRT
PDFs hosted by the registry, ClinicalTrials.gov.
Started Mar 2020 (actual). Primary completion is estimated for Jan 2027, 82 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.